Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Integra Lifesciences (IART)

$44.81 0.00 (0.00%)

16:24 EDT IART Stock Quote Delayed 20 Minutes

Volume:

Previous Close $44.81

Market Cap 3.94B

PE Ratio 50.92

EPS 0.88

Volume (Avg. Vol.)

Day's Range 44.81 - 44.81

52-Week Range 34.21 - 65.09

Dividend & Yield N/A (N/A)

IART Stock Predictions, Articles, and Integra Lifesciences News

From the Web

Integra LifeSciences sees drop in Q1 revenue amid COVID-19 (NASDAQ:IART)

From Seeking Alpha Apr 7, 2020

On a preliminary basis, Integra LifeSciences Holdings (NASDAQ:IART) expects Q1 revenue of $352M - 354M, down almost 2% from a year ago on a reported basis and shy of consensus of $367M.Q2 will be wors

Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods

From Zacks Investment Research Apr 7, 2020

This regulatory clearance is expected to bolster Merit Medical Systems' (MMSI) cardiovascular segment.

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Creating Value For Shareholders?

From Simply Wall St Apr 6, 2020

Today we’ll look at Integra LifeSciences Holdings Corporation (NASDAQ:IART) and reflect on its potential as an investment. Specifically, we’ll consider its Return On Capital Employed (ROCE), since that will give<div><a class="permalink" href="https://simplywall.st/stocks/us/healthcare/nasdaq-iart/integra-lifesciences-holdings/news/is-integra-lifesciences-holdings-corporation-nasdaqiart-creating-value-for-shareholders/">Read More...</a></div>

Here's Why You Should Retain AMN Healthcare (AMN) for Now

From Zacks Investment Research Apr 6, 2020

Investor confidence remains high on AMN Healthcare's (AMN) stock, thanks to solid prospects.

Benzinga's Top Upgrades, Downgrades For April 3, 2020

From Benzinga Apr 3, 2020

Upgrades Raymond James changed the rating for Akamai Technologies Inc (NASDAQ: AKAM) from Market Perform to Outperform. Akamai Technologies earned $1.23 in the...

Jefferies sees 93% upside in Avadel Pharma in premarket analyst action

From Seeking Alpha Apr 3, 2020

Arcus Biosciences (NYSE:RCUS) initiated with Overweight rating and $21 (41% upside) price target at Cantor Fitzgerald.Avadel Pharmaceuticals (NASDAQ:AVDL) initiated with Buy rating and $14 (93% upside

Navellier Ratings

Powered by Portfolio Grader

Total Grade

C

Hold